Navigation Links
Amicus Therapeutics Announces Third Quarter 2008 Financial Results
Date:11/3/2008

apies, Inc. ("Shire"), is engaged in ongoing discussions with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) and will provide an update by the end of the year. A final decision on the global development strategy will follow the conclusion of the discussions with both agencies. Subject to the outcome of the discussions, the Company expects to initiate Phase 3 development of Amigal in the first half of 2009.

In addition, 23 of the original 26 patients continue to be treated in a voluntary Phase 2 extension study designed to monitor long-term safety and efficacy and to evaluate additional doses and dose regimens. Data from this extension study are expected in Q1 2009 prior to the start of the Phase 3 study.

Gaucher Disease:

Plicera(TM) (isofagomine tartrate) is an investigational, oral therapeutic in Phase 2 development for the treatment of Gaucher disease. As previously disclosed, a 6-month Phase 2 clinical trial of Plicera in patients naive to ERT is ongoing and Amicus expects the results of this study to be available in 2009.

Pompe Disease:

AT2220 (1-deoxynojirimycin HCl) is an investigational, oral therapeutic being developed for the treatment of Pompe disease. As previously disclosed, a Phase 2 clinical trial of AT2220 in adult Pompe patients is ongoing and includes an 11 week treatment period with an optional extension study.

In addition, Amicus is conducting preclinical animal studies to evaluate the effects of administering AT2220 in combination with enzyme replacement therapy. Based on the results of the preclinical work, Amicus will consider initiating a clinical trial of the AT2220-ERT combination treatment in Pompe patients.

Other Chaperone Programs:

Amicus continues to invest in research and development to assess the potential for using pharmacological chaperones to treat a broader range of human genetic diseases beyond lysosomal storage diseases. As part of this
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
2. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
3. Amicus Therapeutics Opens Research Facility in San Diego
4. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
5. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
6. Amicus Therapeutics Announces First Quarter 2008 Financial Results
7. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
8. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
11. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015 Pipette.com has added the ... comprehensive portfolio of Eppendorf products. , The Eppendorf Centrifuge ... Centrifuge 5424/5424 R and receive the following:, ... plus or Eppendorf Reference 2 ,     3 ...
(Date:1/22/2015)... NJ (PRWEB) January 22, 2015 ... technologies such as the Bioruptor® and complete solutions ... system for chromatin immunoprecipitation, alleviating the need for ... and controls needed for ChIP of histones or ...
(Date:1/22/2015)... Jan. 22, 2015  Derma Sciences, Inc. (Nasdaq: ... on advanced wound care, announces that AMNIOEXCEL® and ... been added to the Premier, Inc. Regenerative Skin ... for the AMNIOEXCEL® and AMNIOMATRIX® product lines, which ...
(Date:12/24/2014)... Solutions , Inc. (NASDAQ: BLFS ), a leading ... storage and cryopreservation freeze media and ... or the "Company"), today announced that it will hold its ... "Annual Meeting"). Because the expected date for the ...
Breaking Biology Technology:Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5BioLife Solutions Sets Date for Annual Meeting of Stockholders 2
... CHARLOTTESVILLE, Va., Dec. 21 Diffusion Pharmaceuticals,LLC, ... utilizing a novel mechanism of action that ... its key advisors, Mr. Thomas,Byrne, was recently ... of Amgen,s blockbuster drug Aranesp(R) (darbepoietin alpha), ...
... to serve Pacific Northwest, SEATTLE, Dec. 21 ... the western Washington state congressional delegation has,resulted in ... development,of a state-of-the-art proton-beam therapy center by the ... in the 2008 Omnibus Appropriations,bill signed by President ...
... 21 Abbott (NYSE: ABT ),will present at ... 7, 2008. Thomas C. Freyman, executive vice president, finance ... the company at,11:00 a.m. Central time., A live ... Investor Relations Web site at http://www.abbottinvestor.com . An,archived ...
Cached Biology Technology:Co-Inventor of Amgen's Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals' First-in-Class Oxygen Enhancing Therapeutics 2Murray Leads Delegation in Securing $2.1 Million for Proton Therapy Center 2Murray Leads Delegation in Securing $2.1 Million for Proton Therapy Center 3
(Date:1/22/2015)... 22, 2015 , Europe,s ... The European Patent Office to present a video retrospective of ... to be featured: Christofer Toumazou and Sophie Wilson ... and winners of the Award   Starting on 22 ...
(Date:12/22/2014)... Inc. (NASDAQ: NXTD and NXTDW) ("NXT-ID" or ... mobile commerce market, announces it has retained famous pickpocket, entertainer ... International CES debut of the Wocket™ biometric smart wallet.  ... NXT-ID booth January 6th and 7 th , 2015, demonstrating ...
(Date:12/19/2014)... , Dec. 18, 2014  23andMe, Inc., the leading personal genetics ... fine-scale differences in genetic ancestry of individuals from across ... first arrived more than four hundred years ago, ... place for peoples from different continents. This study illuminates how ...
Breaking Biology News(10 mins):Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 423andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4
... Department of Energy,s Oak Ridge National Laboratory and St. ... nerve cells may hold a key to predicting and ... St. Jude scientists have linked movement and changes ... retinas of young mice to certain diseases. Now, for ...
... have 43 percent increased odds of having moderate ... birth compared to mothers of single-born children, according ... of Public Health. Researchers examined the relationship between ... that multiple births increased the odds of maternal ...
... animals of omega 3 fatty acids in fish oils have ... improving meat quality and reducing methane emissions. These last ... is important for the environment, as methane given off by ... Today (Monday 30 March) researchers from University College Dublin reported ...
Cached Biology News:ORNL, St. Jude track neurons to predict and prevent disease 2Mothers of multiple births at increased odds of postpartum depression 2
The HQ505, 20 OptiGreen filter for the Molecular Imager FX is a band pass filter used for detection of Cy2 and FITC with 532 nm excitation....
The filter 530DF28 for the Molecular Imager FX is a band pass filter for ECL Plus, AttoPhos, SYBR Green, Alexa Fluor 488, FITC, Cy2, and Pro-Q Emerald dyes....
... The ApopTag Fluorescein In Situ Apoptosis ... situ by the indirect TUNEL method, ... conjugated to a Fluorescein reporter molecule. ... 40 samples. Results are analyzed using ...
... GT and PowerPac 3000 system, 220-240 V, is ... x 50 cm vertical slab gel format. The ... which is capable of separating nucleic acids with ... chamber (IPC) assembly (IPC and bonded inner glass ...
Biology Products: